Multi-Center, Non-Interventional Study, on the Efficacy of Dual and Triple Therapies Based on Pegylated Interferon Alfa-2a for the Treatment of Chronic Hepatitis C Patients
Phase of Trial: Phase IV
Latest Information Update: 19 Feb 2017
At a glance
- Drugs Peginterferon alfa-2a (Primary) ; Boceprevir; Ribavirin; Telaprevir
- Indications Hepatitis C
- Focus Therapeutic Use
- Sponsors Roche
- 04 Apr 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 02 Nov 2015 Planned End Date changed from 1 Feb 2016 to 1 Dec 2015, according to ClinicalTrials.gov record.
- 02 Nov 2015 Planned primary completion date changed from 1 Feb 2016 to 1 Dec 2015, according to ClinicalTrials.gov record.